Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.
Marketed Products
Regeneron has received marketing approval from the U.S. Food and Drug Administration (FDA) for ARCALYST™ (rilonacept) Injection for Subcutaneous Use for a rare inflammatory condition.
Advanced Product Candidates
In clinical trials for a wide range of solid tumors.
In clinical trials for wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
Regeneron also is evaluating the potential use of rilonacept in other indications in which IL-1 may play a role.
HIGHLIGHTS
The 2008 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc.
will be held on Friday, June 13, 2008 at 10:30 in the morning at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, New York.
Regeneron Reports First Quarter 2008 Financial and Operating Results.
Regeneron and Bayer HealthCare Have Announced Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration.
Career Opportunities
Regeneron is currently seeking world- class talent to join our exclusive team.
